Sugi Predict

Sugi Predict / Compounds / SCHEMBL2856840

SCHEMBL2856840

SCHEMBL2856840

CCOC(=O)c1ccc(-c2ccnc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ ESR2 Q92731 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ PDGFRB P09619 1/20 0.45
▸ PDGFRA P16234 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ SIRT1 Q96EB6 1/20 0.44
▸ SIRT3 Q9NTG7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL959440 0.85 JMJD6 (0.52) LMNANPC1RAB9AMAPTJMJD6
SCHEMBL15907818 0.84 KDM4E (0.50) CA12CA1CA2CA7CA9
SCHEMBL4889753 0.82 MAP4K4 (0.47) CA12CA1CA2ESR1CA7
SCHEMBL1467581 0.81 JMJD6 (0.48) LMNANPC1RAB9AMAPTPOLB
SCHEMBL25854880 0.81 MAPT (0.45) NPC1RAB9ASMN1; SMN2MAPTPOLB
SCHEMBL3956297 0.81 AAK1 (0.48) CA12CA1CA2CA9CA14
SCHEMBL17345209 0.79 MAP4K4 (0.51) NPC1RAB9AMAP4K4SMN1; SMN2ALOX5
SCHEMBL18985455 0.79 PDGFRB (0.49) CA12CA1CA2ESR1CA7
SCHEMBL8031197 0.79 CA12 (0.49) CA12CA1CA2ESR1CA7
SCHEMBL7226376 0.77 KMO (0.57) NPC1RAB9AMAP4K4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF H LEE MOFFITT CANCER CT & RES (US) 2026-04-16 — — US disclosed
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof GLAXOSMITH KLINE LLC (US) 2026-03-10 — — US disclosed
WO-2024035771-A2 ULK3 INHIBITORS AND USES THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-02-15 — — WO disclosed
CN-117304179-A Preparation process of Jactinib dihydrochloride monohydrate 苏州泽璟生物制药股份有限公司 2023-12-29 — — CN disclosed
WO-2023246807-A1 PREPARATION PROCESS FOR JAKTINIB DIHYDROCHLORIDE MONOHYDRATE 苏州泽璟生物制药股份有限公司 2023-12-28 — — WO disclosed
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof SIERRA ONCOLOGY, INC. (US) 2022-12-08 — — US disclosed
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2021-10-07 — — US disclosed
EP-2943489-B1 DEUTERATED MOMELOTINIB CONCERT PHARMACEUTICALS INC (US) 2018-04-11 — — EP disclosed
US-9776973-B2 Deuterated momelotinib CONCERT PHARMACEUTICALS, INC. (US) 2017-10-03 — — US disclosed
US-20170144977-A1 DEUTERATED MOMELOTINIB SUN PHARMACEUTICAL INDUSTRIES, INC. 2017-05-25 — — US disclosed
CN-103370068-A Treatment of JAK-2 mediated disorders YM BIOSCIENCES AUSTRALIA PTY 2013-10-23 — — CN disclosed
EP-2646029-A1 TREATMENT OF JAK2-MEDIATED CONDITIONS YM BioSciences Australia Pty Ltd (AU) 2013-10-09 — — EP disclosed
US-8486941-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-07-16 — — US disclosed
WO-2012149602-A1 MULTIPLE MYELOMA TREATMENT YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2012-11-08 — — WO disclosed
WO-2012071612-A1 TREATMENT OF JAK2-MEDIATED CONDITIONS YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2012-06-07 — — WO disclosed
CN-101861313-A Phenylaminopyrimidine compounds and their use CYTOPIA RES PTY LTD 2010-10-13 — — CN disclosed
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2010-08-05 — — US disclosed
EP-2152701-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF Cytopia Research Pty Ltd (AU) 2010-02-17 — — EP disclosed
WO-2009029998-A1 RETROMETABOLIC COMPOUNDS CYTOPIA RESEARCH PTY LTD (AU) 2009-03-12 — — WO disclosed
WO-2008109943-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF CYTOPIA RESEARCH PTY LTD (AU) 2008-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 CA12 4863/4885CA1 4867/4885CA2 4781/4885
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof JAK1, JAK2, JAK3 CA12 4711/4885CA1 4654/4885CA2 3994/4885
US-20170144977-A1 DEUTERATED MOMELOTINIB ABL1, JAK1, JAK2 CA12 2344/4885CA1 3222/4885CA2 2402/4885
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 CA12 4863/4885CA1 4867/4885CA2 4781/4885
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof JAK2, JAK1, JAK3 CA12 4863/4885CA1 4867/4885CA2 4781/4885
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF ULK3, ULK1, ULK2 CA12 4098/4885CA1 3852/4885CA2 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.